Video Experimental Relacionado
Updated: Sep 9, 2025
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
13.9K
Concentrado de complejo de protrombina de cuatro factores de dosis fija para la reversión de la anticoagulación:
Amer Al Homssi1, Ryan Lokkesmoe2, Ryan Powers1
1Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Journal of hematology
|September 4, 2025
Resumen
La dosificación fija del concentrado de complejo de protrombina de cuatro factores (4F-PCC) ofrece un ahorro significativo de costos para la reversión de la warfarina y el DOAC. Este enfoque demuestra una seguridad y eficacia comparables a los métodos de dosificación tradicionales.
Área de la Ciencia:
- Farmacología y Terapia
- Hematología
- Economía de la salud
Sus antecedentes:
- El concentrado de complejo de protrombina de cuatro factores (4F- PCC) se utiliza para la reversión de la warfarina y el tratamiento no indicado de la hemorragia en pacientes que toman anticoagulantes orales directos (DOAC).
- La optimización de las estrategias de dosificación de 4F-PCC para la eficacia y la rentabilidad, como la dosificación fija, sigue siendo un área de investigación en curso.
Objetivo del estudio:
- Evaluar retrospectivamente la eficacia, la seguridad y el ahorro de costes asociados con la dosificación fija de 4F-PCC.
- Comparar los regímenes de dosis fijas (1.500 UI para la warfarina, 2.000 UI para los DOAC) con la dosificación tradicional basada en el peso y la INR.
Principales métodos:
- Revisión retrospectiva de los registros de pacientes desde octubre de 2018 hasta abril de 2021 en tres hospitales.
- El análisis incluyó a 592 pacientes que recibieron dosis fijas de 4F-PCC para la reversión de la warfarina (n=414) o para el tratamiento de la DOAC (n=127).
- Resultados evaluados: acontecimientos de sangrado/trombosis a los 30 días, requerimientos de dosis repetidas, mortalidad por cualquier causa y ahorro de costes.
Principales resultados:
- En el 89% de los pacientes tratados con warfarina se alcanzó un índice normalizado internacional (INR) inferior a 2.
- Menos del 5% de los pacientes en cualquiera de los grupos requirieron dosis repetidas de 4F- PCC.
- Se informó de ahorros significativos de costos medios por paciente: $ 1,567 para warfarina y $ 3,936 para DOAC, con ahorros anuales sustanciales en el hospital.
Conclusiones:
- La dosificación fija de 4F-PCC es una alternativa rentable a la dosificación ajustada.
- La estrategia de dosificación fija demostró tasas de trombosis y mortalidad comparables a las de los estudios existentes.
- Este enfoque ofrece importantes beneficios financieros a los sistemas de salud sin comprometer la seguridad o eficacia de los pacientes.
Videos de Conceptos Relacionados
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
888
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
888
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
642
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
642
01:30Venous Thrombosis IV: Nursing Management
22
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
22
01:16Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K